SG Americas Securities LLC Has $5.17 Million Stock Holdings in Certara, Inc. $CERT

SG Americas Securities LLC boosted its position in Certara, Inc. (NASDAQ:CERT) by 1,717.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 906,615 shares of the company’s stock after acquiring an additional 856,729 shares during the period. SG Americas Securities LLC owned 0.59% of Certara worth $5,168,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CERT. AQR Capital Management LLC bought a new position in shares of Certara in the 1st quarter valued at about $259,000. Goldman Sachs Group Inc. raised its stake in shares of Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after buying an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after buying an additional 35,954 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after buying an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Certara by 29.3% in the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock valued at $1,089,000 after buying an additional 21,099 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CERT shares. Craig Hallum reduced their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. KeyCorp cut their price target on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Morgan Stanley reduced their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Stephens decreased their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.85.

Certara Stock Down 0.3%

Certara stock opened at $5.83 on Monday. The company’s 50 day simple moving average is $5.58 and its 200 day simple moving average is $6.92. Certara, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $13.88. The firm has a market capitalization of $906.20 million, a price-to-earnings ratio of -58.25 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.24 EPS for the current year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.